Urticaria Drugs Market size to grow by USD 1.31 billion from 2021 to 2026, Driven by the growth in incidence of urticaria - Technavio

NEW YORK, April 4, 2023 /PRNewswire/ -- The global urticaria drugs market size is estimated to grow by USD 1.31 billion from 2021 to 2026, according to Technavio. The market is estimated to grow at a CAGR of 10.35% during the forecast period. Factors such as the growth in the incidence of urticaria, guidelines for the management of urticaria patients, and growing approval of the drugs for urticaria will drive market growth. However, challenges such as the social stigma associated with urticaria may impede market growth. For more insights on the  forecast market size (2021 to 2026) - Request a sample report

Why buy?

• Add credibility to strategy
• Analyzes competitor's offerings
• Get a holistic view of the market

Grow your profit margin with Technavio - Buy the report!

Urticaria Drugs Market – Market Dynamics
Key factor driving market growth

• The increase in the incidence of urticaria is one of the drivers supporting the urticaria drug market growth.
•  Urticaria is a widely prevalent disorder, which results in high medical consultations globally. It negatively impacts the quality of life of people, and most patients are undertreated due to challenges in the affordability of drugs and low access to healthcare due to social stigma. 
• Furthermore, the increasing incidence of allergic disorders and infections is also a major risk factor for the incidence of urticaria globally. 
• The patients are highly immunocompromised, resulting in the release of mast cells and histamines, which causes hives. 
• Hence, the associated risks will fuel the urticaria drugs market growth during the forecast period.

Leading trends influencing the market 

• The introduction of biologics for the treatment of urticaria is one of the urticaria drug market trends that is contributing to the market growth.
• An unmet need for disease-modifying biologics for the treatment of urticaria has been observed, resulting in extensive research centered on the evaluation of safety and efficacy, mechanism of action, and dosing of biologics like XOLAIR (omalizumab), rituximab, and intravenous immunoglobulin for urticaria.
• Furthermore, various controlled studies demonstrated that XOLAIR could be employed successfully in approximately 75% of patients with chronic spontaneous urticaria, leading to a significant decrement in symptoms with very few side effects. 
• Hence, such initiatives are expected to drive the urticaria drugs market growth during the forecast period.

Major challenges hindering the market growth

• The social stigma associated with urticaria is a factor hindering the urticaria drug market growth during the forecast period.
• Urticaria condition is a chronic dermatological condition often associated with social stigma, and the level of stigmatization may also change based on geography. 
• Some countries have low awareness of dermatological conditions.
• Moreover, sometimes dealing with social stigma may lead to mood disorders such as anxiety, depression, and stress, which may negatively impact the quality of life of the patient.
• Hence, life-threatening social stigmas will hamper the urticaria drugs market growth during the forecast period.

Insights on market drivers, trends, & challenges and forecast period (2021 to 2026) - Request a sample report!

Urticaria Drugs Market - Vendor Analysis

Vendor landscape - The global urticaria drugs market is characterized by the presence of vendors of varying sizes offering several products. This has a two-pronged impact on the market. Allakos Inc., Amneal Pharmaceuticals Inc., Aurobindo Pharma Ltd., Bayer AG, F. Hoffmann La Roche Ltd., Genentech Inc., GlaxoSmithKline Plc, Johnson and Johnson, Meiji Holdings Co. Ltd., Novartis AG, Otsuka Holdings Co. Ltd., Sanofi, TerSera Therapeutics LLC, Teva Pharmaceutical Industries Ltd., United BioPharma Inc., and Viatris Inc. are some of the major vendors in the market.

Vendor Offerings

• Allakos Inc. - The company offers Urticaria drugs that minimize the release of mediators throughout the allergic inflammatory cascade. 
• Genentech Inc. - The company offers Urticaria drugs designed to target and block immunoglobulin E used for treating chronic urticaria and asthma patients. 
• F. Hoffmann La Roche Ltd. - The company offers Urticaria drugs that are indicated for the treatment of acute urticaria in adults and children 6 months of age and older. 

Urticaria Drugs Market - Segmentation Assessment
Segment Overview
Technavio has segmented the market based on application (acute urticaria and chronic urticaria) and geography (North America, Europe, Asia, and the Rest of the World (ROW)). 

• The market share growth by the acute urticaria segment will be significant during the forecast period. Acute urticaria is more common than chronic urticaria, as it mostly occurs due to associated allergies, post-viral illnesses, etc. They last less than six weeks and may be managed by antihistamines. Hence, the acute urticaria segment of the global urticaria drugs market is expected to witness accelerating growth in the forecast period. The incidence of acute urticaria is rising owing to the increased prevalence of allergic diseases worldwide. 

Geography Overview
The report provides actionable insights and estimates the contribution of all regions to the growth of the global urticaria drugs market.

• North America is estimated to account for 41% of the market growth during the forecast period. Market growth in this region will be faster than the growth of the market in other regions. The US and Canada are the key markets for the urticaria drugs market in the region. Around 1.5 million individuals in the US develop chronic idiopathic urticaria at some point in their life. Thus, the rising incidence of urticaria and the unmet demand for safe and effective urticaria drugs will facilitate the urticaria drug market growth in the region. 

Insights on the market contribution of various segments including country and region wise, and forecast market size (2021 to 2026) - Download a Sample Report

What are the key data covered in this Urticaria Drugs Market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the urticaria drugs market between 2022 and 2026
• Precise estimation of the size of the urticaria drugs market and its contribution the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the urticaria drugs market across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of urticaria drugs market vendors

Gain instant access to 17,000+ market research reports. 

Technavio's SUBSCRIPTION platform

Related Reports:

The bronchiectasis drugs market size is expected to increase by USD 276.16 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 9.31%. This report extensively covers the bronchiectasis drugs market segmentation by product (antibiotics, expectorants, and others) and geography (North America, Europe, Asia, and the Rest of the World (ROW)). The growing prevalence of associated risk factors is a key factor driving the global bronchiectasis drugs market growth.

The laryngeal cancer therapeutics market size is expected to increase by USD 635.07 million from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 7%. The report extensively covers laryngeal cancer therapeutics market segmentation by type (biologics and small molecules) and geography (North America, Europe, Asia, and ROW). A key factor driving growth in the laryngeal cancer therapeutics market is the increasing prevalence of laryngeal cancer.

Browse for Technavio's Health Care Market Reports 

Table of Contents 

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Application
• Exhibit 06: Executive Summary – Chart on Incremental Growth
• Exhibit 07: Executive Summary – Data Table on Incremental Growth
• Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 11: Offerings of vendors included in the market definition

• 3.2 Market segment analysis
• Exhibit 12: Market segments

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026
• Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary
• Exhibit 17: Five forces analysis - Comparison between2021 and 2026

• 4.2 Bargaining power of buyers
• Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026

• 4.3 Bargaining power of suppliers
• Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants
• Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes
• Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry
• Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

• 4.7 Market condition
• Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Application

• 5.1 Market segments
• Exhibit 24: Chart on Application - Market share 2021-2026 (%)
• Exhibit 25: Data Table on Application - Market share 2021-2026 (%)

• 5.2 Comparison by Application
• Exhibit 26: Chart on Comparison by Application
• Exhibit 27: Data Table on Comparison by Application

• 5.3 Acute urticaria - Market size and forecast 2021-2026
• Exhibit 28: Chart on Acute urticaria - Market size and forecast 2021-2026 ($ million)
• Exhibit 29: Data Table on Acute urticaria - Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Chart on Acute urticaria - Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on Acute urticaria - Year-over-year growth 2021-2026 (%)

• 5.4 Chronic urticaria - Market size and forecast 2021-2026
• Exhibit 32: Chart on Chronic urticaria - Market size and forecast 2021-2026 ($ million)
• Exhibit 33: Data Table on Chronic urticaria - Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Chart on Chronic urticaria - Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on Chronic urticaria - Year-over-year growth 2021-2026 (%)

• 5.5 Market opportunity by Application
• Exhibit 36: Market opportunity by Application ($ million)

6 Customer Landscape

• 6.1 Customer landscape overview
• Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation
• Exhibit 38: Chart on Market share by geography 2021-2026 (%)
• Exhibit 39: Data Table on Market share by geography 2021-2026 (%)

• 7.2 Geographic comparison
• Exhibit 40: Chart on Geographic comparison
• Exhibit 41: Data Table on Geographic comparison

• 7.3 North America - Market size and forecast 2021-2026
• Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)

• 7.4 Europe - Market size and forecast 2021-2026
• Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)

• 7.5 Asia - Market size and forecast 2021-2026
• Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)

• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
• Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

• 7.7 US - Market size and forecast 2021-2026
• Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)

• 7.8 Germany - Market size and forecast 2021-2026
• Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%)
• Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%)

• 7.9 UK - Market size and forecast 2021-2026
• Exhibit 66: Chart on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 67: Data Table on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 68: Chart on UK - Year-over-year growth 2021-2026 (%)
• Exhibit 69: Data Table on UK - Year-over-year growth 2021-2026 (%)

• 7.10 China - Market size and forecast 2021-2026
• Exhibit 70: Chart on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 71: Data Table on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 72: Chart on China - Year-over-year growth 2021-2026 (%)
• Exhibit 73: Data Table on China - Year-over-year growth 2021-2026 (%)

• 7.11 Canada - Market size and forecast 2021-2026
• Exhibit 74: Chart on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 75: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 76: Chart on Canada - Year-over-year growth 2021-2026 (%)
• Exhibit 77: Data Table on Canada - Year-over-year growth 2021-2026 (%)

• 7.12 Market opportunity by geography
• Exhibit 78: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges

• 8.3 Impact of drivers and challenges
• Exhibit 79: Impact of drivers and challenges in 2021 and 2026

• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape
• Exhibit 80: Overview on Criticality of inputs and Factors of differentiation

• 9.3 Landscape disruption
• Exhibit 81: Overview on factors of disruption

• 9.4 Industry risks
• Exhibit 82: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered
• Exhibit 83: Vendors covered

• 10.2 Market positioning of vendors
• Exhibit 84: Matrix on vendor position and classification

• 10.3 Allakos Inc.
• Exhibit 85: Allakos Inc. - Overview
• Exhibit 86: Allakos Inc. - Product / Service
• Exhibit 87: Allakos Inc. - Key offerings

• 10.4 F. Hoffmann La Roche Ltd.
• Exhibit 88: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 89: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 90: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 91: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 92: F. Hoffmann La Roche Ltd. - Segment focus

• 10.5 Genentech Inc.
• Exhibit 93: Genentech Inc. - Overview
• Exhibit 94: Genentech Inc. - Product / Service
• Exhibit 95: Genentech Inc. - Key offerings

• 10.6 GlaxoSmithKline Plc
• Exhibit 96: GlaxoSmithKline Plc - Overview
• Exhibit 97: GlaxoSmithKline Plc - Business segments
• Exhibit 98: GlaxoSmithKline Plc - Key news
• Exhibit 99: GlaxoSmithKline Plc - Key offerings
• Exhibit 100: GlaxoSmithKline Plc - Segment focus

• 10.7 Meiji Holdings Co. Ltd.
• Exhibit 101: Meiji Holdings Co. Ltd. - Overview
• Exhibit 102: Meiji Holdings Co. Ltd. - Business segments
• Exhibit 103: Meiji Holdings Co. Ltd. - Key offerings
• Exhibit 104: Meiji Holdings Co. Ltd. - Segment focus

• 10.8 Novartis AG
• Exhibit 105: Novartis AG - Overview
• Exhibit 106: Novartis AG - Business segments
• Exhibit 107: Novartis AG - Key offerings
• Exhibit 108: Novartis AG - Segment focus

• 10.9 Otsuka Holdings Co. Ltd.
• Exhibit 109: Otsuka Holdings Co. Ltd. - Overview
• Exhibit 110: Otsuka Holdings Co. Ltd. - Business segments
• Exhibit 111: Otsuka Holdings Co. Ltd. - Key offerings
• Exhibit 112: Otsuka Holdings Co. Ltd. - Segment focus

• 10.10 Sanofi
• Exhibit 113: Sanofi - Overview
• Exhibit 114: Sanofi - Business segments
• Exhibit 115: Sanofi - Key news
• Exhibit 116: Sanofi - Key offerings
• Exhibit 117: Sanofi - Segment focus

• 10.11 TerSera Therapeutics LLC
• Exhibit 118: TerSera Therapeutics LLC - Overview
• Exhibit 119: TerSera Therapeutics LLC - Product / Service
• Exhibit 120: TerSera Therapeutics LLC - Key offerings

• 10.12 United BioPharma Inc.
• Exhibit 121: United BioPharma Inc. - Overview
• Exhibit 122: United BioPharma Inc. - Product / Service
• Exhibit 123: United BioPharma Inc. - Key offerings

11 Appendix

• 11.1 Scope of the report

• 11.2 Inclusions and exclusions checklist
• Exhibit 124: Inclusions checklist
• Exhibit 125: Exclusions checklist

• 11.3 Currency conversion rates for US$
• Exhibit 126: Currency conversion rates for US$

• 11.4 Research methodology
• Exhibit 127: Research methodology
• Exhibit 128: Validation techniques employed for market sizing
• Exhibit 129: Information sources

• 11.5 List of abbreviations
• Exhibit 130: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio